Neurocognitive impairment in HIV-infected individuals remains a significant problem despite antiretroviral therapy. There is a critical need for surrogate markers that can be used to predict cognitive impairment and to monitor the effects of antiretroviral, or neuroprotective therapy in HIV-infected individuals. The primary goals of the Surrogate Marker / Pharmacokinetic Core will be to: 1) Assist in the development and monitoring of surrogate markers for HIV-associated neurocognitive disorders (HAND). 2) To provide mentorship and consultation for Neuro-AIDS researchers in the development of clinically useful surrogate markers for HAND and to validate these as predictive and associative markers for cognitive impairment and as surrogate markers for therapeutic effectiveness. An additional task ofthe core will be to assist in the development of small molecule therapeufics by providing consultation on pharamcokinetic/pharmacodynamic considerations for drug development, and conducting pharmacokinetic and analysis of potential drugs and drug metabolites.

Public Health Relevance

HIV/AIDS is a major threat to global health and urban America, and HIV-associated-neurocognitive dysfunction remains prevalent even in HAART-treated people. Our research suggests that one of the drivers for this is sustained inflammation within the brain. Our Center has helped to coordinate and catalyze scientific and clinical resources at JHU to generate novel approaches to therapy

Agency
National Institute of Health (NIH)
Type
Center Core Grants (P30)
Project #
5P30MH075673-09
Application #
8690148
Study Section
Special Emphasis Panel (ZMH1)
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Saylor, Deanna; Dickens, Alex M; Sacktor, Ned et al. (2016) HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment. Nat Rev Neurol 12:234-48
Sacktor, Ned; Skolasky, Richard L; Seaberg, Eric et al. (2016) Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study. Neurology 86:334-40
Anderson, Brian A; Kronemer, Sharif I; Rilee, Jessica J et al. (2016) Reward, attention, and HIV-related risk in HIV+ individuals. Neurobiol Dis 92:157-65
Fazeli, Pariya L; Moore, David J; Franklin, Donald R et al. (2016) Lower CSF Aβ is Associated with HAND in HIV-Infected Adults with a Family History of Dementia. Curr HIV Res 14:324-30
Ramos, Félix M; Delgado-Vélez, Manuel; Ortiz, Ángel L et al. (2016) Expression of CHRFAM7A and CHRNA7 in neuronal cells and postmortem brain of HIV-infected patients: considerations for HIV-associated neurocognitive disorder. J Neurovirol 22:327-35
Kumar, Vivek; Bonifazi, Alessandro; Ellenberger, Michael P et al. (2016) Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid Dependence Treatment. J Med Chem 59:7634-50
Buchanan, Erin L; Espinoza, Diego A; McAlexander, Melissa A et al. (2016) SAMHD1 transcript upregulation during SIV infection of the central nervous system does not associate with reduced viral load. Sci Rep 6:22629
Elgogary, Amira; Xu, Qingguo; Poore, Brad et al. (2016) Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. Proc Natl Acad Sci U S A 113:E5328-36
Clifford, David B; Vaida, Florin; Kao, Yu-Ting et al. (2015) Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people. Neurology 84:241-50
Witwer, Kenneth W; Buchanan, Erin L; Myers, Stephanie L et al. (2015) miRNAs and SAMHD1 regulation in vitro and in a model of HIV CNS disease. J Neuroinflammation 12:159

Showing the most recent 10 out of 126 publications